Abstract:Background Compared with PBO, addition of APA to ADT significantly improved radiographic progression-free survival (rPFS [HR, 0.48; 95% CI, 0.39-0.60; p Methods mCSPC pts (N = 1052) were randomized 1:1 to APA (240 mg QD; n = 525) or PBO (n = 527). All pts received ADT. Pts were stratified by Gleason score at diagnosis (≤ 7 vs > 7), region (North America vs European Union vs other countries), and prior docetaxel use (yes vs no). PROs were assessed using the Brief Pain Inventory-Short Form (BPI-SF), Brief Fatigue Inventory (BFI), Functional Assessment of Cancer Therapy-Prostate (FACT-P), and Euro QoL Group EQ-5D-5L. BPI and BFI were completed for 7 consecutive days (D) (D -6 plus D1 of each cycle [C] visit), then at Months 4, 8, and 12 in follow-up. FACT-P and EQ-5D-5L were completed C1 through C7, then every other C through end of treatment (tmt), and at Months 4, 8, and 12 in follow-up. Analyses included descriptive statistics and mean change from baseline using mixed model of repeated measures. Results Pts were relatively asymptomatic at baseline: on 0-10 severity scales, median pain scores were 1.14 (APA) and 1.00 (PBO), and median fatigue scores were 1.29 (APA) and 1.43 (PBO). Pt experience of pain and fatigue (both intensity and interference) was similar between groups for the duration of tmt. For the majority of pts in both arms, pain and fatigue remained stable or improved during tmt, with greater improvements observed in pts with higher baseline severity scores. FACT-P total score and EQ-5D-5L data showed similar maintenance of overall HRQoL in both arms. Similar tolerability was experienced between groups based on the FACT-P single item side effects bother question. Conclusions The addition of APA to ADT maintained overall HRQoL while significantly improving OS and rPFS in mCSPC pts. Clinical trial identification NCT02489318. Editorial acknowledgement Chris R. Prostko, PhD, of Parexel. Legal entity responsible for the study Janssen Research & Development. Funding Janssen Research & Development. Disclosure N. Agarwal: Advisory / Consultancy: Argos Therapeutics; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Eisai; EMD Serono; Exelixis; Foundation One Inc; Genentech/Roche; Lilly; Medivation/Astellas; Merck; Nektar; Novartis; Pfizer; Research grant / Funding (institution): Active Biotech; Amgen; AstraZeneca; Bavarian Nordic; Bayer; BN ImmunoTherapeutics; Bristol-Myers Squibb; Calithera Biosciences; Celldex; Eisai; Exelixis; Genentech; GlaxoSmithKline; Immunomedics; Janssen; Medivation; Merck; Newlink Genetics. K. McQuarrie: Full / Part-time employment: Janssen; Shareholder / Stockholder / Stock options: Johnson & Johnson. A. Bjartell: Shareholder / Stockholder / Stock options: Glactone Pharma AB. S. Chowdhury: Honoraria (self), Advisory / Consultancy: Clovis Oncology; Honoraria (self): Novartis; Advisory / Consultancy: Astellas Pharma; Advisory / Consultancy: Bayer; Advisory / Consultancy: Janssen-Cilag; Advisory / Consultancy, Speaker Bureau / Expert testimony: Pfizer; Research grant / Funding (institution): Sanofi/Aventis. B.H. Chung: Honoraria (self), Advisory / Consultancy: Astellas (Korea); Honoraria (self), Advisory / Consultancy: Ipsen (Korea); Honoraria (self): JW Pharma (Korea); Honoraria (self): Takeda (Korea); Advisory / Consultancy: Janssen (Korea); Advisory / Consultancy: Handok (Korea); Research grant / Funding (self): Janssen (USA); Research grant / Funding (self): Bayer (Germany); Research grant / Funding (self): Pfizer (USA); Research grant / Funding (self): AstraZeneca (UK). Juarez Soto: Advisory / Consultancy, Research grant / Funding (self): Janssen; Advisory / Consultancy: Astellas; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Coloplast; Research grant / Funding (self): Bayer. A. Merseburger: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Janssen-Cilag; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Astellas. H. Uemura: Honoraria (self), Travel / Accommodation / Expenses: Janssen; Honoraria (self): Astellas; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Takeda; Honoraria (self), Travel / Accommodation / Expenses: Sanofi; Honoraria (self), Travel / Accommodation / Expenses: Bayer; Advisory / Consultancy: AstraZeneca. R. Given: Shareholder / Stockholder / Stock options: Multiple companies as individual stock and within mutual funds; Honoraria (self): HealthTronics; Speaker Bureau / Expert testimony, Research grant / Funding (self): Janssen; Research grant / Funding (self): Ferring; Research grant / Funding (self): Veru; Research grant / Funding (self): Medivation; Research grant / Funding (self): Clovis. B. Miladinovic: Full / Part-time employment: Janssen Research & Development; Shareholder / Stockholder / Stock options: Johnson & Johnson. L. Dearden: Full / Part-time employment: Janssen Research & Development; Shareholder / Stockholder / Stock options: Johnson & Johnson. K. Deprince: Full / Part-time employment: Janssen Research & Development; Shareholder / Stockholder / Stock options: Johnson & Johnson. V. Naini: Full / Part-time employment: Janssen Research & Development; Shareholder / Stockholder / Stock options: Johnson & Johnson. A. Lopez-Gitlitz: Full / Part-time employment: Janssen Research & Development; Shareholder / Stockholder / Stock options: Johnson & Johnson. K.N. Chi: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Astellas Pharma; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Bayer; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Sanofi; Advisory / Consultancy: Amgen; Advisory / Consultancy: ESSA; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Janssen; Advisory / Consultancy, Research grant / Funding (institution): Lilly/ImClone; Research grant / Funding (institution): Bristol-Myers Squibb; Research grant / Funding (institution): Merck; Research grant / Funding (institution): Roche; Research grant / Funding (institution): Tokai Pharmaceuticals. All other authors have declared no conflicts of interest.

Patient-reported outcomes (PROs) with talazoparib (TALA) plus enzalutamide (ENZA) vs. placebo (PBO) plus ENZA in men with metastatic castration-resistant prostate cancer (mCRPC): Subgroup analysis of patients with novel hormonal therapy (NHT) pretreatment in the TALAPRO-2 study.

TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations.

Patient reported outcomes (PROs) among patients with metastatic castration-resistant prostate cancer (mCRPC) by homologous recombination repair mutations (HRRm) gene clusters: Findings from the phase 3 TALAPRO-2 study cohort 2.

TALAPRO-2: a placebo-controlled phase III study of talazoparib (TALA) plus enzalutamide (ENZA) for patients with first-line metastatic castration-resistant prostate cancer (mCRPC).

Comparative efficacy and safety of talazoparib plus enzalutamide and other first-line treatments for metastatic castration-resistant prostate cancer

Abstract CT018: TMPRSS2-ERG and RB1 as candidate predictive biomarkers for efficacy in TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Exploratory analyses of homologous recombination repair (HRR) gene subgroups and potential associations with secondary efficacy endpoints in the HRR-deficient population from TALAPRO-2.

First-line Talazoparib with Enzalutamide in HRR-deficient Metastatic Castration-Resistant Prostate Cancer: the Phase 3 TALAPRO-2 Trial

Patient-reported Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Harboring DNA Damage Response Alterations Treated with Talazoparib: Results from TALAPRO-1

Plain language summary of the results from the TALAPRO-2 study: Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer

1829P Exposure-safety Analyses of Talazoparib in Combination of Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer (mcrpc) in TALAPRO-2 Trial

Post hoc analysis of rPFS and OS from the TALAPRO-2 (TP-2) study: Genomic subgroups based on likelihood of BRCA or HRR gene alteration status.

The TALAPRO-3 study design: a plain language summary

Talazoparib plus enzalutamide versus olaparib plus abiraterone acetate and niraparib plus abiraterone acetate for metastatic castration-resistant prostate cancer: a matching-adjusted indirect comparison

Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: an Asian Multiregional, Randomized Study.

Health-related Quality of Life (hrqol) and Patient-Reported Outcomes at Final Analysis of the TITAN Study of Apalutamide (APA) Versus Placebo (PBO) in Patients (pts) with Metastatic Castration-Sensitive Prostate Cancer (mcspc) Receiving Androgen Deprivation Therapy (ADT).

EMBARK post hoc analysis of sexual activity (SA) patient-reported outcome (PRO) measures.

OncoFlash–Research Updates in a Flash! (Mar 2024)

Patient-reported Outcomes (pros) from TITAN: A Phase III, Randomized, Double-Blind Study of Apalutamide (APA) Versus Placebo (PBO) Added to Androgen Deprivation Therapy (ADT) in Patients (pts) with Metastatic Castration-Sensitive Prostate Cancer (Mcspc)